Objective-Investigate role of dose/duration of zoledronic acid (ZOL), a powerful anti-resorptive (pAR), on prevalence of medication-related osteonecrosis of the jaw (MRONJ) in rice rats (Oryzomys palustris), a species with natural susceptibility to food impaction-induced localized periodontitis (FILP). We hypothesize that ZOL induces MRONJ lesions in rice rats with FILP, and that the prevalence of MRONJ rises with increasing dose and duration of ZOL treatment.
Introduction
Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event in humans primarily associated with powerful anti-antiresorptive (pAR) drugs, including nitrogen-containing bisphosphonates (N-BPs) [1] [2] [3] [4] [5] and receptor activator of NFκB ligand (RANKL) antibodies [6] [7] [8] . It is also associated with anti-angiogenic therapies, such as tyrosine kinase and vascular endothelial growth factor inhibitors [9] [10] [11] . The American Association of Oral and Maxillofacial Surgeons (AAOMS) defines MRONJ as exposed bone, or bone that can be probed through a fistula in the maxillofacial region that has persisted for more than eight weeks in patients with no history of radiation therapy to the jaws, no obvious metastatic disease in the jaws, and a history of pARs and/or antiangiogenic therapy [12] .
The role of the medications implicated in the etiology and pathophysiology of MRONJ has not been fully elucidated. Randomized, prospective human studies indicate that oncologic doses of ZOL, and longer duration of ZOL treatment, increase MRONJ incidence. For instance, a trial of 3300 women taking oncology doses of ZOL, reported increasing cumulative MRONJ incidence in the ZOL group, with a maximum of 2.1% after six years treatment [13] [14] [15] , compared to a 0.0% cumulative incidence in the non-ZOL group. In comparison, a trial of over 8000 women taking ZOL for osteoporosis (OP) reported a cumulative MRONJ incidence of only ~0.01% with a dose that was only 10-fold lower than that used in oncology patients [16] . Despite these findings, the dose relationship between ZOL and MRONJ incidence appears to be disproportionate, given the ~200-fold lower incidence in OP patients that occurs at a dose only 10-fold lower than the oncology doses. Furthermore, the relatively low prevalence of MRONJ among patients receiving even the highest doses of pARs [13] [14] [15] , raises a strong likelihood that risk factors other than the medications themselves are crucial [17, 18] .
The localization MRONJ to the jaws suggests that pre-existing or coinciding oral risk factors play an important role in the disease. Multiple preclinical experiments have already investigated aspects of event-related MRONJ by observing tooth extraction-related healing in pAR-treated small animals [19] [20] [21] [22] [23] [24] [25] [26] [27] . Reducing event-related MRONJ incidence by strategically timing tooth extractions in pAR patients is a highly successful recommendation already in place [28, 29] . In contrast, spontaneous MRONJ, which accounts for one third of all cases, is inherently more difficult to prevent and treat due to the absence of an identifiable precipitating event. Spontaneous MRONJ, appears to be associated with oral inflammation and infection, including periodontitis (PD) and periapical infection [27, [30] [31] [32] [33] [34] . PD is a bacteria-driven inflammatory disease of the periodontium, and is an important risk factor for both spontaneous and event-related MRONJ [1, 4, 12, 28, 29] . However, there have been no prospective studies to formally investigate the dose and duration relationship between pARs and MRONJ in animals affected by oral infection or inflammatory conditions, such as PD.
The rice rat (Oryzomys palustris) spontaneously develops two distinctive types of PD. When fed a high sucrose casein diet (HSC), rice rats develop a well-described generalized form of PD by age 12-18 weeks [35] [36] [37] [38] [39] . Furthermore, when combined with intravenous (IV) oncologic doses of pARs (clodronate, alendronate, or ZOL), HSC-fed rice rats develop MRONJ-like lesions in alveolar bone [32, 40] . More recently, rats fed standard rodent chow (STD) have been shown to develop food impaction-induced localized periodontitis (FILP) [41] , which is distinctive from the generalized PD seen in HSC-fed rice rats. FILPs occur with 1) high prevalence of ~60-80% between ages 16-34 weeks; 2) consistent location at the palatal aspect of the interdental space between theM2M3 maxillary molars; and 3) relatively stable size and severity level in untreated rats. These features suggest that the FILP rice rat model could be used in toxicology studies that address the interaction of oral infection and inflammation with pARs, or other medications, that may cause MRONJ.
The purpose of this study was two-fold: 1) generate pre-clinical evidence that a pAR induces MRONJ in FILP-affected rats; and 2) conduct a toxicology study in FILP-affected rats that examines the relationship of MRONJ prevalence to increasing dose and duration of pAR treatment. We hypothesize that ZOL induces MRONJ lesions in rice rats with FILP and that the prevalence of MRONJ rises with increasing dose and duration of ZOL.
Materials and methods

Animal care
A monogamous continuous-breeding system was used to generate pups for the studies. At weaning (age 4 weeks), clinically normal females [BW ≥ 30 g and body condition score (BCS) ≥ 3.0] [42] were randomized into the experiment, with efforts made to distribute littermates among different groups. Experimental animals ate STD diet (Envigo Teklad LM-485 (irradiated 7912) Rodent Diet; Tampa, FL USA). BW was measured bi-weekly. Rats with BW loss and/or BCS deterioration were offered gel diet and supplemental fluids. Breeder animals ate rodent breeder chow (Envigo Teklad, irradiated 2919). All rats were housed (2-5 rats per cage) in static filter top cages (area: 143 in. 2 ) with pine shavings as bedding and continuous access to food and water. The housing room was maintained at 68-79 °F with an average humidity of 30-70% and a 12:12 h light:dark cycle. Breeder pairs were housed in the same conditions as experimental rats, but with a 14:10 h light:dark cycle. The Animal Care Services resource at the University of Florida (UF) is an AAALACaccredited animal care and use program. Both protocols were approved by the UF Institutional Animal Care and Use Committee (IACUC).
Study design
2.2.1. Study 1: effects of an oncologic dose of ZOL-The extent that MRONJ lesions could be induced in STD diet rice rats prone to FILP lesions was examined. We hypothesized that STD-fed rice rats IV-injected with oncologic ZOL (80 µg/kg) every 4 weeks (q4wk) would develop MRONJ. Female rice rats (n = 48, age 4 weeks) were fed STD diet and injected in the tail vein with either vehicle (saline, ZOL0, N = 24) or ZOL80 (N = 24) starting at age 4 weeks, and then every four weeks, thereafter. Half the rats from each group were randomly euthanized after 12 weeks (age 16 weeks) and the remainders were euthanized after 18 weeks (age 22 weeks).
Study 2:
effects of ZOL dose and duration on MRONJ prevalence-Two hundred thirty female rice rats were BW-randomized into a baseline necropsy group (N = 12, age 4 weeks), or one of five dose groups (N = 43-54) (Fig. 1) . All groups were fed STD diet and received IV injections of 0, 8, 20, 50 or 125 µg/kg of ZOL q4wk, starting at age four weeks [43] . These doses encompass the osteoporosis (8 µg/kg) and oncologic doses (20-125 µg/kg) of ZOL (see below).
After 12, 18, 24 and 30 weeks of treatment, duration sub-groups (N = 9-16) of rats from each of the five dose groups were necropsied. Rats were pre-assigned to dose groups at the start of the experiment, but not to duration sub-groups. Each duration subgroup was populated with rats that had lost ≥15% BW from its maximum, in order to comply with humane endpoints specified in the IACUC protocol. The rest of the group was completed by BW-randomization. No more than 25% of the rats in each subgroup were preselected as a result of reaching endpoint criteria for euthanasia due to BW lost.
ZOL dose and duration explanation
The minimum dose of ZOL that fully blocks ovariectomy-induced bone loss in adult rats is 8 µg/kg IV q4wk [44] , but there are no predictive animal studies that have tested oncology outcomes of ZOL, such as prevention of bone metastases and hypercalcemia of malignancy. The ZOL oncology dose for Study 1 was 80 µg/kg BW, 10-fold higher than the OP ZOL dose. This was estimated from the 9.6:1 ratio (roughly 10-fold) of oncologic (48 mg IV/yr) to OP (5 mg IV/yr) ZOL in human medicine. The doses for Study 2 ranged from 8 to 125 µg/kg, to include both the OP dose and several doses in an oncologic range (20-125 µg/kg). ZOL was dissolved in normal saline (pH 7.2) and injected at 1 ml/kg BW IV. Zoledronic acid was kindly provided by Novartis Pharma AG (Basel, Switzerland).
Although our previous findings indicate that MRONJ lesions could be induced by 80 µg/kg ZOL in HSC diet rice rats after 18-22 weeks, the duration of this study was extended to 30 weeks since duration and cumulative exposure appear to play important roles in MRONJ. Cumulative dose, not dosing interval, is the primary determinant of N-BP efficacy [45] . Our oncology dose represents pre-clinical dose-interval combinations that yield a cumulative dose of 240 µg/kg quarterly or 40 µg/kg 2×/mo.
Euthanasia and tissue collection
Rats were euthanized by CO 2 inhalation followed by cervical dislocation. Maxillae and mandibles were excised and trimmed, leaving gingiva and oral mucosa intact. When necessary, saline irrigation was used to remove excessive accumulation of bacterial plaque that obscured molars. High resolution (HR) photographs from the ventral aspect of each hemi-maxilla (Fig. 2) and medial aspect of each hemimandible (Supplemental Fig. 1 ) were taken with a digital camera (Canon EOS 6D; Tokyo, Japan) attached to a macro lens (Canon EF 100 mm 1:2.8; Tokyo, Japan). The right femur was disarticulated from the acetabulum and separated from the tibia. All tissue samples were fixed in freshly prepared 4% paraformaldehyde at 4 °C for 48 h then transferred to 70% ethanol for storage at 4 °C.
Gross analysis of oral lesions
2.5.1. Identification and grading of gross oral lesions-Photographs of jaws were analyzed independently in a blinded fashion by three observers (JGM, DBK, JIA). Quadrants were assigned a gross quadrant grade (GQG) (0-4, or MRONJ) ( Table 1) . Photographs of representative maxillae and mandibles at each GQG are shown in Fig. 2A and Supplemental Fig. 1A , respectively. Pocket depth or clinical attachment level evaluation by probing was not completed. When GQG was not consistent between investigators jaws were re-examined as a group to reach consensus. When at least one quadrant from a rat had a GQG ≥ 3 that included an area of exposed bone, the rat was considered positive for gross MRONJ. 2 ) of gross oral lesions in each quadrant with GQG ≥ 1 were measured using the outline tool as previously described using AxioVision SE64 Rel software version 4.9.1 (Carl Zeiss, Germany) [41] . Total maxillary area (Tt.Mx.Ar) was demarcated mesially by a perpendicular line mesial to M1; caudally, a perpendicular line distal to M3, dorsally, a line along the gingival margins, and approximating the mesial and distal lines; and ventrally, a longitudinal line, along the sagittal palatal line, and approximating the mesial and distal lines ( Table 1) were measured in random order by one investigator blinded to GQG (JIA).
Quantification of gross oral lesion area-The areas (mm
Histopathological assessment of oral lesions
2.6.1. Specimen selection, preparation, and examination of jaw quadrant sections-All quadrants containing a gross MRONJ lesion, and any quadrant with GQG 1-4 underwent histopathological examination to identify and/or confirm exposed, necrotic bone (see below). Quadrants were decalcified in 5% formic acid under gentle agitation for four weeks, with three acid changes per week. Decalcified quadrants were trimmed to include the molar region, surrounding alveolar bone, and, for maxillae, the hard palate. Tissue was paraffin-embedded, and serially sectioned in the mesio-distal plane at 5-µm thickness at five to six different levels for quadrant. Each level was separated by about 250 µm. Multi-level examination of each quadrant was conducted on palatal or lingual tissues (one or two levels), interdental regions (M1M2, M2M3; three levels), and buccal regions (one level). Leica/Jung 2265 and Accu-Cut SRM 200 Sakura microtomes were used to section (Sakura Finetek Europe B.V, Zoeterwoude, The Netherlands). Sections were stained with H&E and coverslipped, and analyzed by one observer, blinded to the GQG.
Histological definition of MRONJ lesion-MRONJ
lesions were defined histologically as bone that was both exposed and necrotic in at least one level within a quadrant. Exposed bone was identified by a lack of overlying soft tissue including gingival epithelium, lamina propria, connective tissue, and periodontal ligament (PDL) (Fig. 5 ). Necrotic bone was defined as a region of bone matrix containing ≥10 adjacent empty osteocyte lacunae, or lacunae with pyknotic osteocyte nuclei, as previously described [46, 47] . These lacunae occasionally appeared enlarged and/or contained cellular debris. Exposed necrotic bone was almost always associated with adherent bacterial plaque. When at least one quadrant in a rat was assigned a histopathologic diagnosis of MRONJ, the rat was considered positive for histopathologic MRONJ.
Histological quantification of empty osteocyte lacunae-To assess necrotic
bone the number of lacunae that were empty or contained pyknotic nuclei were counted. Data collection was performed at 200× magnification in sections within a 0.15-0.25 mm 2 region of interest (ROI) that contained exposed bone matrix in an MRONJ lesion or an area of bone with periodontal tissue destruction and inflammation in FILP lesions with GQG ≥ 1.
Total bone area (Tt.Ar;mm 2 ), total number of osteocyte lacunae (#OtLc), and number of empty osteocyte lacunae (#Em.OtLc) were measured. The number of lacunae per bone area (density of osteocyte lacunae; #OtLc/mm 2 ), number of empty lacunae per bone area (#Em.OtLc/mm 2 ), and percentage of empty lacunae (100 × #Em.OtLc / #Ot.Lc) were calculated. For analysis, means were calculated from quadrants with 1) FILP lesions with GQG 1; 2) FILP lesions with GQG 2; 3) FILP lesions with GQG 3-4; 4) MRONJ lesions identified solely by histology; or 5) gross MRONJ lesions confirmed histologically.
Peripheral quantitative computed tomography (pQCT)
pQCT analysis of the right femur was used to verify the antiresorptive efficacy of ZOL. Femurs were scanned at 1 mm-thick cross sections using a Stratec XCT Research M instrument (v 5.40, Norland Medical Systems; Fort Atkinson, WI). Sites of interest were 5 mm proximal to the distal end of the femur (total metaphysis), and at the longitudinal midpoint of the femur (mid-diaphysis). Volumetric bone mineral content (vBMD, mg), volumetric bone mineral density (vBMD, mg/cm 3 ), and cortical area (mm 2 ) were determined for total bone (trabecular and cortical bone at the metaphysis, and cortical bone at the mid-diaphysis), as previously described [48] .
Statistical analysis
Data are expressed as mean ± SD for each group, except BW which is express as mean ± SEM. For Study 1, Fisher's Exact test was used to assess prevalence of MRONJ lesions in ZOL0 and ZOL80 groups at 12 and 18 weeks. For Study 2, data were evaluated to assess intergroup differences using one-way ANOVA with Holm-Sidak post hoc tests for BW, percent of empty osteocyte lacunae, and vBMD, vBMD and cortical bone area. When assumptions of data normality were not met, a Kruskal-Wallis ANOVA test followed by Dunn's multiple comparison was applied. Multiple logistic regression was used to test the effects of ZOL dose/duration on MRONJ prevalence. Pearson correlation test was used to test for an association between FILP GQG and the area (mm 2 ) of oral lesions. P values <0.05 were considered statistically significant.
Results
3.1. Study 1 3.1.1. ZOL0-FILP lesions were generally discrete and localized at the lingual surface of the interdental area of M2M3, with minimal/moderate gingival recession ( Fig. 2A ; GQG = 1-3). 75% of rats had FILP lesions in at least one maxilla was after 12 and 18 weeks (Fig.  3) . FILP GQGs ranged from 1 to 3, with a median of 1 (data not shown). No differences in GQG or FILP.Ar/T.Ar were observed between rats on STD diet for 12 vs. 18 weeks (data not shown). Similar to previous findings, no FILP or PD-like lesions were observed in the mandible [41] (Fig. 3) , and no rats developed MRONJ.
ZOL80-Like
ZOL0, 75% of ZOL80 rats showed FILP lesions in at least one maxilla (Fig. 3) , ranging from QGQ1-4, with median GQG2 (data not shown). FILP lesions tended to be larger and more severe in ZOL80 rats than in time-matched ZOL0 rats, with greater areas of recession/ulceration often involving the entire gingival margin of M2M3 ( Fig. 2A; GQG scores 3-4) . Some ZOL80 rats also had gross oral lesions in mandibles similar to PD lesions that have been previously reported in rice rats [32] (Fig. 3;  Supplemental Fig. 1A ).
Unlike ZOL0 rats, ZOL80 rats had gross maxillary MRONJ lesions at 12 and 18 weeks, with a prevalence of 25% and 50%, respectively (Fig. 3) . In maxillae, MRONJ lesions were found at locations where FILP lesions also developed ( Fig. 2A) . MRONJ lesions were never observed in mandibles (Fig. 3) . Histopathologic analysis confirmed the existence of exposed, necrotic bone in all gross MRONJ cases. Prevalence of MRONJ lesions was associated with jaw (maxilla) and ZOL treatment (P < 0.001).
Study 2: dose and duration effects of ZOL on MRONJ prevalence
3.2.1. Prevalence of rats with gross MRONJ-No MRONJ lesions were present at four weeks. The prevalence of rats with MRONJ by ZOL dose and treatment duration is shown (Fig. 4A) . ZOL dose (P < 0.001), but not duration of ZOL treatment (P = 0.297), was a significant predictor of MRONJ. The overall prevalence of gross MRONJ in the whole study was 13%. The prevalence of rats with MRONJ was 22% in rats receiving oncologic doses of ZOL (≥20 µg/kg), which was significantly greater than 0 or 8 µg/kg (P < 0.001 and P < 0.001, respectively).
Four quadrants were missing, broken, or the HR photo was of insufficient quality for analysis. Supplemental Table 1 shows Le.Ar, expressed as Le.Ar/Tt.Ar, and number of GQG (0-4) and MRONJ lesions by arch and ZOL dose. At age 4 weeks (baseline), rats had no MRONJ or FILP lesions. A total of 916 jaw quadrants were given a GQG. At ages [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] weeks, 573 quadrants were lesion-free (63%; 41% of maxillae and 84% of mandibles). More maxillary quadrants than mandibular quadrants had lesions (P < 0.001). A positive correlation was found between lesion area and GQG (Pearson r = 0.867), independent of dose and duration of ZOL (Supplemental Table 1 ). Table 1 ) were distributed among 29 rats. There were no MRONJ lesions in control or OP ZOL (8 µg/kg) rats. All 29 rats with MRONJ lesions had at least one maxilla with an MRONJ lesion. 79% of MRONJ lesions were in the maxilla (P < 0.001 vs mandible). Mandibular MRONJ lesions were never found without accompanying maxillary MRONJ lesions. Fig. 6A and B) . ZOL0 rats had FILP lesions with GQG ≤ 3, but never had MRONJ. FILP lesions displayed substantial hyperplasia of the gingival epithelium; inflammatory cell infiltration of the lamina propria ( Fig. 6A and B) ; PDL disruption; apical migration of the junctional epithelium; and alveolar bone crest resorption. Isolated, empty osteocyte lacunae were occasionally observed, but most lacunae were occupied by round basophilic osteocyte nuclei (Figs. 6B).
MRONJ lesions (Supplemental
Histopathological analysis-FILP
We found that 96% of quadrants with gross MRONJ lesions (54/56) contained exposed necrotic bone, and that all 29 rats with gross MRONJ lesions fulfilled the histopathologic criteria for an MRONJ positive case (Figs. 5, 6C, and D) . We identified an additional 53 rats, not diagnosed with gross MRONJ, that had at least one quadrant with histopathologic features of MRONJ [GQG 1 (n = 0/100), GQG 2 (n = 15/96), 3 (n = 28/71), or 4 (n = 10/20)].
There was a significantly higher percentage of empty osteocyte lacunae (P < 0.001) (Fig.  6E ) and a greater number of empty osteocyte lacunae/mm 2 (P < 0.001) (Fig. 6F ) in MRONJ lesions than in GQG 1-4 quadrants not diagnosed with MRONJ. No differences in these endpoints were found between gross and histopathologic MRONJ lesions ( Fig. 6E and F) . Fig. 4B shows the prevalence of rats with histopathological MRONJ by dose and duration. The prevalence of rats with histopathologic MRONJ in the whole study populations was 38%. The prevalence of histopathologic MRONJ in rats exposed to oncologic doses of ZOL (≥20 µg/kg) was 73%, with most cases occurring at ≥18 weeks. Several duration groups had 100% prevalence of MRONJ (Fig. 4B) . Only 5% of MRONJ cases occurred in rats given 8 µg/kg ZOL (OP dose), all at 30 weeks (Fig. 4B) . ZOL dose (P < 0.001), but not duration (P=0.326), was a predictor of histopathologic MRONJ prevalence (Fig. 4B) . Prevalence in ZOL-treated rats was 31% (13/42); 62% (26/42); 57% (23/40), and 36% (20/55) at 12, 18, 24 and 30 weeks, respectively. To examine the effect of pre-selecting rats for necropsy due to BW loss on the effect of ZOL duration on MRONJ prevalence, ZOL-treated rats with BW loss were removed from the analysis at the 12 (n = 6), 18 (n = 16), and 24 week (n= 10) time points, and data were re-analyzed. When BW loss cases were removed, MRONJ prevalence was 19, 38, 43, and 36% at 12, 18, 24, and 30 weeks, respectively, and both ZOL dose (P < 0.001) and duration (P = 0.017) were significant predictors of MRONJ prevalence ( Supplemental  Fig. 4) . The proportion of rats with histopathologic MRONJ within each GQG was also determined (Supplemental Fig. 5 ). There were no cases of histopathologic MRONJ in animals with GQG 0 or 1. In rats with GQG 2, 3, and 4 the proportion of animals with MRONJ was about 40, 80, and 100%, respectively, at each time point.
Prevalence of rats with histopathologic MRONJ-
Body weight-BW
of rats in all experimental groups increased with age throughout the study, with no significant effects of ZOL (Supplemental Fig. 2A) . However, when this study population was grouped into rats that had either gross MRONJ, histopathologic-only MRONJ, or PD 0, we found significantly lower BW in rats with gross MRONJ compared to GQG 0 rats at 12-24 weeks of ZOL treatment (Supplemental Fig. 2B ). In addition, BW were lower in rats with histopathologic-only MRONJ, but only at week 24 of ZOL treatment compared with GQG0 rats (Supplemental Fig. 2B ).
Anti-resorptive efficacy of ZOL in the femur-Total metaphyseal vBMD and
vBMD, and cortical area were significantly greater in all ZOL groups compared to the ZOL 0 group (P < 0.001) at all time points (Supplemental Fig. 3A-C) . Cortical BMC was higher in groups treated with ZOL only after 18 weeks compared to ZOL 0 (Supplemental Fig. 3D ). Total metaphyseal vBMD and vBMD; and cortical bone area and BMC were significantly greater at ZOL doses ≥20 µg/kg compared to ZOL dose 8 µg/kg, particularly at 24 and 30 weeks (P < 0.05) (Supplemental Fig. 3A-D ).
Discussion
These studies demonstrate that MRONJ can be induced in rice rats fed a STD diet when simultaneously given clinically relevant doses of ZOL at both the osteoporosis and oncology range. The MRONJ lesions in this model resemble those seen in human MRONJ, and were localized primarily to the same location where FILP lesions occurred. Additionally, higher doses of ZOL were associated with higher prevalence of MRONJ. To our knowledge, this is the first experiment to show a dose response relationship between clinically relevant doses of ZOL and MRONJ prevalence.
Our results show that the prevalence of histopathological MRONJ was 0% in the ZOL0 group, 5% in rats given the OP dose (8 µg/kg), and 73% in rats given oncology doses of ZOL (20-125 µg/kg), indicating that higher doses of ZOL are associated with more prevalent MRONJ. MRONJ lesions were found after 12 weeks, reaching peak prevalence at 18 weeks after 5 monthly injections of ZOL oncology doses. This treatment regimen produced cumulative doses of 100, 250, and 625 µg/kg for the 20, 50, and 125 µg/kg doses, respectively at peak prevalence. MRONJ prevalence in groups of rice rats given oncologic doses of ZOL was 40-100% within 18-24 weeks of treatment, and appeared to plateau around the 50 µg/kg dose. Therefore, MRONJ in the rice rat FILP model occurs with sufficient prevalence, and in a reasonable amount of time, to allow future studies that can effectively address strategies to prevent or treat MRONJ.
MRONJ prevalence did not appear to be associated with duration in this study. The lower prevalence of MRONJ in rice rats at 30 weeks may be due to the necropsy of rats with greater than 15% BW loss at the earlier time points. Shorter durations may have been disproportionately populated with rats that required earlier necropsy, leading to an artificially high proportion of healthy rats at later time points, reducing MRONJ prevalence at 30 weeks. Moreover, analysis of MRONJ prevalence at each time point after removing animals with BW loss resulted in a significant duration effect on MRONJ prevalence, supporting this idea. These findings appear to contrast with, human studies where cumulative MRONJ incidence increased steadily at 39, 59, and 74 months at 0.7% [13] , 1.1% [14] , and 2.1% [15] , respectively. However, these clinical findings could also reflect new cases of event-related MRONJ related to discrete dental events (e.g., tooth extractions, etc.) that occurred during the follow-up period. Cases of human MRONJ have also been known to spontaneously heal. Therefore, the 30 week time point may have also included rats resistant to FILPs or with MRONJ lesions that had spontaneously healed.
Histopathological analysis revealed that MRONJ in rice rats was similar to human MRONJ [4, 29, [49] [50] [51] [52] , in that both show exposed necrotic bone with confluent areas of empty osteocyte lacunae that is frequently colonized by bacteria. Observation of tissues in serial sections were especially valuable because we were able to fully characterize the appearance of the lesions, identify multiple areas where necrotic bone may have existed, and therefore confidently determine positive MRONJ cases. Importantly, empty osteocyte lacunae were never present beneath fully intact gingiva. If necrotic bone had an epithelial covering in one level, then necrotic bone without an epithelial covering was always found in an adjacent level of the same quadrant. This finding may suggest that MRONJ could be present in persons taking pARs, under gingiva that is recessed or ulcerated that lacks overtly exposed bone.
Although there is no direct human equivalent to the GQG scoring system, this analysis was valuable as a preclinical tool to quickly identify lesion-free quadrants, and quadrants with gross MRONJ. Gross analysis was particularly important because visibly exposed necrotic bone is one of the primary criteria for the diagnosis of MRONJ in humans. Subsequent histopathologic examination of gross MRONJ lesions confirmed the presence of exposed necrotic bone in 95% of these cases, indicating that we were able to accurately identify MRONJ cases when animals had severe lesions with frank bone exposure. The GQG system was also a practical laboratory tool that enabled efficient prioritization of quadrants for sectioning and subsequent histopathological examination. In fact, the histopathological examination of less severe gross lesions (GQG 1-4) revealed nearly three-fold as many cases of MRONJ as gross analysis alone. GQG1 never had histopathological MRONJ, but GQG 2-4 had increased prevalence of histopathological MRONJ (Supplemental Fig. 5) . One of the primary features distinguishing the levels of severity was the extent of gingival ulceration, and larger lesions tended to be more likely to have exposed bone (Supplemental Table 1 ). GQG2 was marked by recession/ulceration of gingival tissue around impacted materials, while GQG1 was characterized only by the presence of impacted materials between the molars without ulceration or marked recession. This finding suggests that GQG2 may represent a grossly identifiable initial stage of a MRONJ-lesion that may have histopathological MRONJ in this model.
Our findings support the idea that gingival/mucosal lesions may be an identifiable nonsurgical dental event in ZOL patients that triggers what has been previously termed "spontaneous" MRONJ. Our data raise the possibility that ZOL negatively affects the healing of oral lesions, thereby contributing to higher risk of MRONJ [22, 26] . Previous animal studies have also shown a link between "spontaneous" MRONJ and oral risk factors other than tooth extraction [30] [31] [32] [33] [34] . These studies induced MRONJ by combining pARs with infection and inflammatory conditions in rodents, including experimental PD, and exposure of the dental pulp to induce periapical infection [27, [30] [31] [32] [33] [34] . One other study has taken advantage of spontaneous oral events that require no mechanical manipulation or dentoalveolar surgical procedures, by using C57BL/6J mice that is prone to maxillofacial abscesses. Like FILPs in rice rats, those lesions are characterized by impacted hair and food debris. Similar to our study, these lesions also progressed to MRONJ when mice were given ZOL [53] .
The MRONJ lesions in this study were localized to the same quadrants, and the same anatomical location as FILPs. Therefore, this model of MRONJ appears to primarily affect the maxilla, rather than then mandible, where human MRONJ is more commonly observed in humans. The majority of untreated rice rats developed at least one FILP lesion by 12 weeks, and the highest FILP lesion prevalence preceded the time point of the highest ZOLassociated MRONJ prevalence. Furthermore, 73% of ZOL-treated rats that had at least one quadrant with GQG ≥ 1 had MRONJ. These data suggest that FILP lesions in rice rats initiate MRONJ in ZOL-treated rats. Further studies are required to establish that ZOLinduced MRONJ in STD diet-fed rice rats is linked directly to the prior or concurrent development of a FILP lesion. Specifically, these experiments would require oral exams in live animals which would track the initiation and clinical progression of both FILPs and MRONJ. The visibility and predictable location of these lesions would also allow intervention studies that reduce the frequency of impaction by removing impacted materials, or preventing impactions by dietary alterations.
A subpopulation of rice rats (45%) treated with oncologic ZOL doses for 30 weeks never developed any FILP or MRONJ lesions. An additional 28% of such rats had minor lesions that were never more severe than GQG=1. This may indicate that some rice rats are resistant to the development of ZOL-induced MRONJ, even with a cumulative ZOL dose up to 1000 µg/kg over 30 weeks. Differential susceptibility in rice rats may be, at least partly, due to individual tooth/gingival morphology that facilitates the retention of impacted materials in some rats, or some rats may have an immune response that permits progression of FILP lesions into MRONJ lesions. It is possible that dental cofactors are integral to the development of MRONJ in ZOL-treated rats and that "resistant" rats never develop those dental cofactors. A MRONJ-resistant subpopulation of rice rats also has clinical implications because the majority of pAR-treated patients also never develop MRONJ.
FILP lesions appear to be a localized reaction to the hair and food debris impacted in the interdental space. In humans, food impaction lesions have been reported in follow-ups of implant prostheses [54] , inducing peri-implantitis [17] , and in embrasures between implantsupported fixed dental prostheses and adjacent teeth [18] . The rice rat FILP may also be comparable to oral clinical conditions that result from debris (e.g. food or fibers) retained between teeth, and in periodontal pockets, that can cause gingivitis, periodontitis, halitosis, pain, gingival abscess, alveolar bone loss, and root caries [55] . FILPs may therefore replicate the discrete injury, and subsequent inflammatory response, seen in humans with such problems. Compared to humans, however, FILPs with GQG 2-4 with gingival ulceration along the gingival margin, are more severe than food impaction lesions typically found in humans. The lack of progression of food impaction lesions in pAR treated humans could be due to the daily oral hygiene practices employed by most humans.
Although this study included a range of osteoporosis and oncology doses of ZOL in a large number of rice rats, the study design has several limitations. MRONJ due to pAR treatment is an adverse event that occurs in patients first exposed to pARs in adulthood. Though the majority of ZOL injections in these experiments were given when the rat skeleton had reached young adulthood, each rat received two ZOL injections when the rat skeleton is considered juvenile (ages 4 and 8 weeks). The initial skeletal distribution and subsequent redistribution of N-BPs differs significantly between the juvenile and adult skeletons, due to the rapid rate of bone modeling-associated bone resorption and formation that is found only in the juvenile skeleton [56] . Therefore, bone modeling in the juvenile skeleton may have played a role in MRONJ pathophysiology in this experiment that could not exist in adult humans, since adults display mostly bone remodeling activity. Future rice rat MRONJ studies in which pARs and anti-angiogenic agents are given only after age 12 weeks, when the rat skeleton is no longer rapidly growing, would assist in resolving this limitation.
In humans, MRONJ diagnosis is made only after bone exposure of eight weeks duration [12, 28, 29] . Reliance on photographs taken at necropsy for the gross analysis did not allow verification of the length of bone exposure before necropsy, and perhaps contributed to underestimation of MRONJ because diagnostic criteria that are available in the clinical setting (e.g., periodontal pocket probing, patient-reported pain, dental radiography, cone beam CT, etc.) cannot be achieved in a rodent study. The inability to determine the duration of bone exposure, raises the possibility that some MRONJ lesions may have been present for less than eight weeks at necropsy. Therefore, lesions may have been identified at a higher prevalence than if we had strictly used criteria applied to humans. Longitudinal observation would also allow observation of spontaneous healing of MRONJ. Spontaneous healing of MRONJ, or gradual healing during daily use of antiseptic mouth rinses, is known to occur in humans [12, 28, 29] .
Conclusion
Powerful anti-resorptives provide unparalleled benefits to patients with both cancer and osteoporosis by reducing mortality and comorbidities associated with both diseases [57] [58] [59] [60] . Despite the existence of MRONJ, the risk-benefit ratio for pARs is strongly positive [12, 28, 29, 61, 62] . Therefore, the use of pARs in patients with cancer and osteoporosis will continue. Our findings raise the possibility that dental cofactors are an important element that can lead to the development of MRONJ when they are present prior to, or develop during, ZOL treatment. Our findings support the use of STD-diet fed rice rats as an animal model prone to a local periodontal event that can be used to clarify the pathophysiology of MRONJ. Prevention and intervention strategies for MRONJ are needed to manage the concerns of both patients and the dental and medical communities over this potentially severe adverse event.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Study design. Two hundred thirty weanling female rice rats were BW-randomized into a baseline necropsy group (N = 12, age 4 weeks), or one of five dose groups (N = 43-54) Five doses of ZOL (0, 8, 20, 50, or 125 µg/kg) were given IV (tail vein) once every four weeks (q4wks), starting at age 4 weeks. Duration subgroups of 9-16 rice rats were necropsied (diamonds) after 12, 18, 24, and 30 weeks of treatment for each dose level. Prevalence of gross oral lesions (study 1). In ZOL0 rats, the prevalence of GQG = 1-4 oral lesions in the maxilla was 75% at both 12 and 18 weeks treatment. Mandibles had no oral lesions at either time point. In ZOL80 rats, the prevalence of GQG = 1-4 oral lesions (non-MRONJ) in the maxilla was 50% at 12 weeks and 17% at 18 weeks. The prevalence of MRONJ lesions in the maxilla was 25% at 12 weeks and 50% at 18 weeks. The prevalence of GQG = 1-4 oral lesions (non-MRONJ) in the mandible was 17% at both time points. Prevalence of MRONJ lesions (study 2). (A) Prevalence of rats with gross MRONJ by ZOL dose and duration. Prevalence increased with increasing ZOL dose (P < 0.001), but not increasing duration of ZOL exposure (P=0.297). Gross MRONJ lesions were not found in ZOL0 or osteoporosis (OP) ZOL (8 µg/kg) groups. (B) Prevalence of rats with histopathologic MRONJ by time and ZOL dose in quadrants with GQG ≥ 1. Prevalence of histopathologic MRONJ increased with increasing ZOL dose (P < 0.001) but not increasing duration of ZOL exposure (P = 0.326). Histopathologic MRONJ was never found in ZOL0 rats; two cases were present in the OP ZOL (8 µg/kg) group at 30 weeks. Histologic features of MRONJ lesions in ZOL-treated rats. Necrotic bone in MRONJ lesions was predominantly present in maxillae at (A) palatal and/or (C and E) M2M3 interdental space. B, D, and F are magnified fields of the rectangles demarcated in A, C, and E, respectively. (A, C, E) MRONJ lesions with characteristic exposed bone (black arrows) lacking overlying gingival epithelium, lamina propria, connective tissue, and PDL. Large fields of empty osteocyte lacunae (B, D, F) that were occasionally enlarged, containing nuclear debris (Ω). Adherent bacterial colonies resembling Actinomyces sp. (yellow asterisks) were frequently found on exposed bone. Dotted black line demarcates a region with extensive necrotic bone (Ω), overlying a region of vital bone (α) (A and B). Severe inflammatory cell infiltration and fibrosis were often observed surrounding necrotic palatal and alveolar bone ( †). Five-µm sections stained with H&E. 
